# AML Multi-Omics Integration: Comprehensive Analysis Roadmap

**Generated:** 2025-10-02

**Author:** AML Multi-Omics Project Team

---

## Executive Summary

This roadmap outlines **10 prioritized analyses** across 3 tiers:

- **TIER 1 (Highest Priority):** 4 core multi-omics analyses
- **TIER 2 (High Priority):** 3 advanced integration analyses
- **TIER 3 (Medium Priority):** 3 exploratory analyses

### Available Cohort Sizes

| Data Type Combination | Sample Size |
|----------------------|-------------|
| Expression only | n = 707 |
| Mutations only | n = 871 |
| Drug Response only | n = 603 |
| Clinical only | n = 934 |
| Expression + Mutations | n = 615 |
| Expression + Drug | n = 494 |
| Mutations + Drug | n = 583 |
| **Gold Standard (all 4)** | **n = 478** |
| Survival data | n = 942 (565 events) |

---

## TIER 1: Core Multi-Omics Analyses (HIGHEST PRIORITY)

These analyses form the foundation of the multi-omics integration project and should be completed first.

### Analysis 1.1: Molecular Subtyping via Expression

**Goal:** Identify transcriptomic subtypes in AML

**Methods:** Consensus clustering, hierarchical clustering, k-means

**Data Requirements:** Expression data

**Sample Size:**
- Required: n ≥ 100
- Available: n = 707

**Statistical Power:** 0.90

**Feasibility:** YES
- *Justification:* n=707 with min cluster size ~141

**Timeline:** 2-3 weeks

**Scripts Location:** `02_Scripts/04_Molecular_Subtyping/`

**Deliverables:**
- Cluster assignments for each sample
- Subtype-specific gene signatures (DEGs per cluster)
- Heatmaps showing cluster-specific expression patterns
- PCA/t-SNE plots with cluster annotations
- Biological interpretation via pathway analysis (GSEA, Reactome)
- Clinical correlation of subtypes (survival, age, mutations)

---

### Analysis 1.2: Comprehensive Mutation Landscape

**Goal:** Characterize mutational profile of AML cohort

**Methods:** Mutation frequency, co-occurrence analysis, mutual exclusivity

**Data Requirements:** Mutation data

**Sample Size:**
- Required: n ≥ 200
- Available: n = 871

**Statistical Power:** 0.90

**Feasibility:** YES
- *Justification:* n=871, can detect mutations ≥5.7%

**Timeline:** 1-2 weeks

**Scripts Location:** `02_Scripts/04_Molecular_Subtyping/`

**Deliverables:**
- OncoPrint visualization of top driver mutations
- Mutation frequency bar plots (overall and by subtype)
- Co-occurrence and mutual exclusivity matrix
- Mutational signature analysis (if WGS data available)
- Driver vs passenger mutation classification
- Comparison with TCGA-AML and other public datasets

---

### Analysis 1.3: Mutation-Expression Integration

**Goal:** Understand how mutations affect gene expression

**Methods:** Differential expression analysis stratified by mutation status

**Data Requirements:** Expression + Mutation data

**Sample Size:**
- Required: n ≥ 50
- Available: n = 615

**Statistical Power:** 0.90

**Feasibility:** YES
- *Justification:* n=615, 10/10 mutations powered

**Timeline:** 2-3 weeks

**Scripts Location:** `02_Scripts/06_Integration/`

**Deliverables:**
- DEG lists for each mutation (FDR < 0.05, |log2FC| > 1)
- Volcano plots for key mutations
- Pathway enrichment analysis (KEGG, Reactome, GO)
- Gene Set Enrichment Analysis (GSEA) using MSigDB
- Heatmaps of top differentially expressed genes
- Mutation-specific expression signatures

**Key Comparisons:** DNMT3A; NPM1; NRAS; TET2; IDH2

---

### Analysis 1.4: Drug Response Prediction from Multi-Omics

**Goal:** Predict drug sensitivity using expression + mutations

**Methods:** Machine learning (Random Forest, Elastic Net, XGBoost)

**Data Requirements:** Expression + Mutations + Drug Response

**Sample Size:**
- Required: n ≥ 150
- Available: n = 478

**Statistical Power:** 0.85

**Feasibility:** YES
- *Justification:* n=478, Train/Val/Test: 286/95/97

**Timeline:** 3-4 weeks

**Scripts Location:** `02_Scripts/05_Drug_Response/`

**Deliverables:**
- Predictive models for top 20 drugs (Random Forest, Elastic Net, XGBoost)
- Feature importance rankings (genes + mutations)
- Cross-validation performance metrics (R², RMSE, MAE)
- Independent test set validation
- Biomarker identification (top predictive features)
- Drug-specific response signatures

---

## TIER 2: Advanced Integration Analyses (HIGH PRIORITY)

These analyses build upon Tier 1 results and provide deeper biological insights.

### Analysis 2.1: Survival Analysis with Multi-Omics Features

**Goal:** Identify prognostic biomarkers from multi-omics data

**Methods:** Cox regression, Kaplan-Meier curves, risk stratification

**Data Requirements:** Survival + Clinical + Expression + Mutations

**Sample Size:**
- Required: n ≥ 100
- Available: n = 942

**Statistical Power:** 0.90

**Feasibility:** YES
- *Justification:* n=942, 565 events (60.0%)

**Timeline:** 2-3 weeks

**Scripts Location:** `02_Scripts/07_Survival_Analysis/`

**Deliverables:**
- Univariate Cox regression for all features
- Multivariate Cox model with top features
- Kaplan-Meier curves for risk groups
- Risk score calculation and validation
- Time-dependent ROC curves
- Prognostic signature identification

---

### Analysis 2.2: Mutation-Drug Response Associations

**Goal:** Identify mutation-specific drug sensitivities/resistances

**Methods:** Stratified AUC comparison, effect size calculation

**Data Requirements:** Mutations + Drug Response

**Sample Size:**
- Required: n ≥ 40
- Available: n = 583

**Statistical Power:** 0.80

**Feasibility:** YES
- *Justification:* n=583, key pairs have ≥20 per group

**Timeline:** 2-3 weeks

**Scripts Location:** `02_Scripts/05_Drug_Response/`

**Deliverables:**
- Mutation-stratified drug sensitivity plots
- Effect size calculations (Cohen's d) for each pair
- Statistical testing (t-test, Mann-Whitney U)
- Volcano plot of mutation-drug associations
- Precision medicine implications
- Actionable biomarkers for drug selection

**Key Associations:** FLT3 vs FLT3 inhibitors (Sorafenib, Gilteritinib); IDH1 vs IDH inhibitors (Ivosidenib); IDH2 vs IDH inhibitors (Enasidenib); DNMT3A vs Hypomethylating agents (Azacitidine); NPM1 vs Venetoclax

---

### Analysis 2.3: Integrated Network Analysis

**Goal:** Construct multi-omics interaction networks

**Methods:** Correlation networks, pathway analysis, module detection

**Data Requirements:** Expression + Mutations + Drug Response

**Sample Size:**
- Required: n ≥ 100
- Available: n = 478

**Statistical Power:** 0.80

**Feasibility:** YES
- *Justification:* n=478 for integrated networks

**Timeline:** 3-4 weeks

**Scripts Location:** `02_Scripts/06_Integration/`

**Deliverables:**
- Gene-gene correlation networks
- Mutation-expression regulatory networks
- Drug-target-expression networks
- Module detection (WGCNA or similar)
- Hub gene identification
- Network-based biomarker discovery

---

## TIER 3: Exploratory Analyses (MEDIUM PRIORITY)

These analyses are exploratory and can be performed after Tier 1-2 completion.

### Analysis 3.1: Subtype-Specific Drug Sensitivities

**Goal:** Identify drugs with differential sensitivity across subtypes

**Methods:** ANOVA, pairwise comparisons, effect size calculation

**Data Requirements:** Expression + Drug Response (requires Analysis 1.1)

**Sample Size:**
- Required: n ≥ 60
- Available: n = 494

**Statistical Power:** 0.80

**Feasibility:** YES
- *Justification:* n=494, ~165 per subtype

**Dependencies:** Requires Analysis 1.1 completion

**Timeline:** 2 weeks

**Scripts Location:** `02_Scripts/05_Drug_Response/`

**Deliverables:**
- Subtype-stratified drug sensitivity plots
- ANOVA results for all drugs
- Subtype-specific drug rankings
- Precision medicine recommendations
- Heatmap of subtype-drug associations

---

### Analysis 3.2: Clinical-Molecular Correlations

**Goal:** Associate clinical features with molecular profiles

**Methods:** Correlation analysis, stratified comparisons

**Data Requirements:** Clinical + Expression + Mutations

**Sample Size:**
- Required: n ≥ 100
- Available: n = 478

**Statistical Power:** 0.70

**Feasibility:** YES
- *Justification:* n=478 with complete clinical data

**Timeline:** 1-2 weeks

**Scripts Location:** `02_Scripts/06_Integration/`

**Deliverables:**
- Age vs expression/mutation associations
- Sex-stratified molecular profiles
- Prior treatment vs molecular features
- WBC count vs expression signatures
- Clinical subgroup comparisons (ELN risk, FAB classification)

---

### Analysis 3.3: Drug Combination Synergy Analysis

**Goal:** Identify synergistic drug combinations

**Methods:** Correlation analysis, synergy scoring (if combination data available)

**Data Requirements:** Drug Response (multiple drugs per sample)

**Sample Size:**
- Required: n ≥ 100
- Available: n = 603

**Statistical Power:** 0.60

**Feasibility:** LIMITED
- *Justification:* n=603, but single-drug screening limits analysis

**Caveat:** Limited by single-drug screening design

**Timeline:** 2-3 weeks

**Scripts Location:** `02_Scripts/05_Drug_Response/`

**Deliverables:**
- Drug-drug correlation matrix
- Predicted synergistic pairs (correlation-based)
- Pathway-based combination hypotheses
- Literature-validated combinations

---

## Estimated Timeline

| Tier | Analyses | Total Time | Can Run in Parallel |
|------|----------|------------|---------------------|
| **Tier 1** | 4 analyses | 8-12 weeks | Some analyses (1.1, 1.2) |
| **Tier 2** | 3 analyses | 7-10 weeks | Yes, after Tier 1 |
| **Tier 3** | 3 analyses | 5-7 weeks | Yes, flexible |

**Total estimated time:** 20-29 weeks (5-7 months) if performed sequentially

**With parallelization:** 12-18 weeks (3-4.5 months)

## Feasibility Summary

| Analysis ID | Analysis Name | Feasibility | Power |
|-------------|---------------|-------------|-------|
| 1.1 | Molecular Subtyping via Expression | YES | 0.90 |
| 1.2 | Comprehensive Mutation Landscape | YES | 0.90 |
| 1.3 | Mutation-Expression Integration | YES | 0.90 |
| 1.4 | Drug Response Prediction from Multi-Omics | YES | 0.85 |
| 2.1 | Survival Analysis with Multi-Omics Features | YES | 0.90 |
| 2.2 | Mutation-Drug Response Associations | YES | 0.80 |
| 2.3 | Integrated Network Analysis | YES | 0.80 |
| 3.1 | Subtype-Specific Drug Sensitivities | YES | 0.80 |
| 3.2 | Clinical-Molecular Correlations | YES | 0.70 |
| 3.3 | Drug Combination Synergy Analysis | LIMITED | 0.60 |

**Summary:** 9/10 analyses are fully feasible with available data.

## Recommendations

1. **Start with Tier 1 Core Analyses:**
   - Begin with Analysis 1.1 (Molecular Subtyping) and 1.2 (Mutation Landscape) in parallel
   - These are foundational and inform downstream analyses

2. **Prioritize Well-Powered Analyses:**
   - 9/10 analyses have adequate statistical power
   - Focus on these for high-confidence results

3. **Sequential Dependencies:**
   - Analysis 3.1 requires completion of Analysis 1.1 first
   - Plan workflow accordingly

4. **Resource Allocation:**
   - Tier 1: Allocate primary resources and personnel
   - Tier 2: Begin after Tier 1 completion
   - Tier 3: Optional/exploratory based on time and resources

5. **Quality Control:**
   - Apply batch correction before expression-based analyses
   - Use gold standard cohort (n=478) for integrated analyses
   - Validate key findings across independent cohorts if possible
